- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles2 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
VVUS Market Currents
more »
-
May 10 Other drug stocks are reacting to the FDA decision on Arena Pharmaceuticals (ARNA) Locaserin: OREX +10%, VVUS +2.3%
2 Comments[Healthcare, On the Move]
VVUS in Focus
more »
VVUS Related Articles
more »
VVUS News
more »
-
at CNBC.com (May 11, 2012)
-
at CNBC.com (May 11, 2012)
-
at CNBC.com (Apr 27, 2012)
-
at CNBC.com (Apr 10, 2012)
-
at CNBC.com (Apr 10, 2012)
VVUS Press Releases and Filings
more »
-
GlobeNewswire (May 7, 2012)
-
GlobeNewswire (May 4, 2012)
-
GlobeNewswire (May 1, 2012)
-
PR Newswire (Apr 27, 2012)
-
GlobeNewswire (Apr 20, 2012)
VVUS Latest Transcript
more »
VVUS Cramer
more »
VVUS Instablog posts
more »
VVUS vs. ETF Alternatives
Company Description
VIVUS, Inc. is a biopharmaceutical company, incorporated in 1991, dedicated to the development and commercialization of therapeutic products for large underserved markets. Our investigational drugs currently under development could serve the obesity, diabetes and sexual health markets. Our... More
